Sulfaphenazole: Benchmark CYP2C9 Inhibitor for Drug Metabolism & Vascular Research

Executive Summary: Sulfaphenazole (CAS No. 526-08-9) is a highly selective, competitive inhibitor of cytochrome P450 enzymes CYP2C6 and CYP2C9, demonstrating an IC₅₀ of 0.63 μM for CYP2C9 under standardized in vitro conditions (Chen et al., 2021). This sulfonamide exerts potent antibacterial activity against Mycobacterium tuberculosis, including XDR-TB, by inhibiting bacterial dihydropteroate synthase (DHPS). Sulfaphenazole exhibits low cytotoxicity (IC₅₀ >64 μg/mL on Vero cells) and favorable solubility in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasound). Its established safety and multi-parameter utility make it indispensable for studies in drug metabolism, oxidative stress reduction, and tissue repair (APExBIO).

Biological Rationale

Sulfaphenazole is a 4-aminobenzenesulfonamide originally developed as an antibacterial agent. Its molecular scaffold mimics 4-aminobenzoic acid, a precursor required for folic acid biosynthesis in bacteria (Chen et al., 2021). The compound’s selectivity for mammalian CYP2C9 and CYP2C6 isoforms enables researchers to investigate cytochrome P450-mediated drug metabolism and adverse drug reactions. Sulfaphenazole's antibacterial properties are particularly relevant for tuberculosis (TB), including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, where inhibition of DHPS disrupts bacterial viability. Its established lack of significant off-target effects allows for precise modulation of oxidative stress pathways and restoration of vascular endothelial function in disease models. The product is widely used in pharmacogenetics, vascular research, and anti-TB compound screening (internal review).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole acts through two principal mechanisms:

• CYP2C9 Inhibition: Sulfaphenazole is a competitive inhibitor of human CYP2C9, binding to the enzyme’s active site and blocking substrate metabolism. The reported IC₅₀ for CYP2C9 is 0.63 μM, with a Ki of 0.3 ± 0.1 μM under standard buffer conditions (pH 7.4, 37°C) (Chen et al., 2021; internal benchmark).
• DHPS (Bacterial) Inhibition: As a structural analogue of 4-aminobenzoic acid, Sulfaphenazole competitively inhibits bacterial dihydropteroate synthase, disrupting tetrahydrofolic acid biosynthesis. This pathway is essential for nucleotide synthesis and bacterial survival (Chen et al., 2021).

These dual mechanisms underpin its use both as an antibacterial and as a tool compound for elucidating CYP2C9-mediated drug interactions, pharmacogenetics, and oxidative stress modulation.

Evidence & Benchmarks

• Sulfaphenazole inhibits recombinant human CYP2C9 with an IC₅₀ of 0.63 μM, confirming high selectivity and potency (Chen et al., 2021).
• It displays in vitro antimycobacterial activity against M. tuberculosis H37Rv with MICs in the range of 5–30 μg/mL (Chen et al., 2021).
• Animal models of diabetic vascular dysfunction show that daily intraperitoneal administration at 5.13 mg/kg restores endothelium-dependent vasodilation and reduces ischemia-reperfusion injury (Chen et al., 2021).
• Cell viability assays demonstrate low cytotoxicity, with IC₅₀ >64 μg/mL in Vero cells, supporting its safety profile (Chen et al., 2021).
• Sulfaphenazole enhances healing of pressure and thermal injury wounds through reduced inflammation, fibrosis, and increased macrophage bactericidal activity (Chen et al., 2021).

This article extends the data-driven insights of Sulfaphenazole (C4131): Reliable CYP2C9 Inhibition for Advanced Drug Metabolism Research by detailing precise activity metrics and usage conditions, offering a deeper mechanistic perspective for experimentalists.

For broader context, see Sulfaphenazole: Benchmark CYP2C9 Inhibitor for Drug Metabolism Studies, which covers its role in pharmacogenetics, and Scenario-Driven Best Practices with Sulfaphenazole (SKU C4131), which provides protocol-level workflow integration. This article details recent peer-reviewed evidence and expands on optimal parameterization.

Applications, Limits & Misconceptions

Sulfaphenazole’s primary applications include:

• Selective inhibition of CYP2C9 and CYP2C6 for drug metabolism studies.
• Benchmark tool for pharmacogenetic analysis and adverse drug reaction risk assessment.
• Antibacterial research targeting Mycobacterium tuberculosis, including XDR-TB.
• Mitigation of oxidative stress and restoration of vascular function in diabetic and ischemia-reperfusion models.
• Promotion of tissue repair, with evidence for reduced fibrosis and improved macrophage function.

Common Pitfalls or Misconceptions

• Not all CYP enzymes are equally inhibited: Sulfaphenazole is selective for CYP2C9 and CYP2C6; it does not significantly inhibit CYP3A4, CYP2D6, or other major isoforms (Chen et al., 2021).
• Limited solubility in aqueous buffers: The compound is insoluble in water; DMSO or ethanol (with ultrasound) must be used for dissolution. Precipitation may occur at high concentrations or during dilution (APExBIO).
• Not suitable for chronic oral dosing in vivo: Most animal efficacy studies use daily intraperitoneal injection; oral bioavailability and pharmacokinetics in humans are not established.
• Bacterial selectivity restricted to DHPS-expressing pathogens: Sulfaphenazole is ineffective against bacteria lacking the DHPS pathway or with acquired resistance.
• Potential for drug–drug interactions: As a potent CYP2C9 inhibitor, Sulfaphenazole can alter the metabolism of co-administered drugs metabolized by CYP2C9 (use with caution in polypharmacy models).

Workflow Integration & Parameters

Sulfaphenazole (SKU C4131) from APExBIO is supplied as a crystalline solid and should be stored at –20°C. For laboratory use, dissolve in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL, with ultrasound). Short-term stock solutions should be kept refrigerated and protected from light to ensure stability. Common working concentrations:

• 0.5–11.5 μM for CYP enzyme inhibition assays.
• 5–30 μg/mL for in vitro anti-tuberculosis experiments.
• 1–10 μM for cell-based oxidative stress and tissue repair studies.
• 5.13 mg/kg per day (i.p.) for animal models of vascular dysfunction.

Careful titration is recommended to avoid non-specific effects at higher concentrations. Controls must be included to account for vehicle (DMSO or ethanol) effects. APExBIO provides extensive product documentation and technical support for Sulfaphenazole users (product page).

Conclusion & Outlook

Sulfaphenazole remains a gold-standard, selective CYP2C9 inhibitor and antibacterial tool compound for advanced biomedical research. Its validated selectivity, safety, and broad utility underpin its adoption in pharmacogenetics, drug metabolism modulation, and infectious disease research. Ongoing structural optimization continues to yield derivatives with improved profiles for anti-tuberculosis therapy (Chen et al., 2021). APExBIO’s Sulfaphenazole (C4131) provides the reproducibility, documentation, and quality assurance required for high-impact mechanistic studies.